About AIM ImmunoTech Inc
- Industry: Biotechnology
- Exchange: NYSE MKT LLC
- Country: US
- Website: https://aimimmuno.com/
Frequently Asked Questions
What is the 52-week range for AIM?
The 52-week high is $2.79 and the 52-week low is $0.1659.
What is the P/E ratio for AIM?
The P/E ratio data is currently unavailable.
What is the dividend yield for AIM?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -138.03%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -15021.05%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.10.
Analyst Recommendation Trends
Wall Street analyst consensus for AIM over the last few months:
Latest AIM News
AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data
Recent biotech media features focus on Ampligen’s potential to address immune resistance in metastatic pancreatic cancer and the clinical progress of the Phase 2 DURIPANC programOCALA, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted recent media coverage focused on the Company’s development strategy for Ampligen® (rintatolimod) in metastatic pancreatic cancer, including the scientific rationale for targeting immune resis
AIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video
Company highlights supportive survival observations, potential for biomarker-driven patient selection and upcoming Phase 2 DURIPANC milestones Access it here OCALA, Fla., Sept. 30, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the release of a new installment of its CEO Corner series featuring Chief Executive Officer Thomas K. Equels discussing how Ampligen® (rintatolimod) could fit into the evolving treatment landscape for pancreatic
AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib
Company CEO outlines the differentiated mechanism and clinical potential of Ampligen in pancreatic cancer Survival data highlighted in accompanying chart show Ampligen-associated median overall survival of 34.8 months in a selected pancreatic patient population versus 12.5 months in historical controls OCALA, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today issued a letter to stockholders from Chief Executive Officer Thomas Equels a
AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video
Company continues to advance Phase 2 DURIPANC study and broader clinical strategy evaluating Ampligen’s potential to reshape the tumor microenvironment and enhance checkpoint inhibition Access it here OCALA, Fla., Sept. 09, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the release of a new installment of its CEO Corner series featuring Chief Executive Officer Thomas K. Equels discussing the Company’s scientific strategy and continued a
The trading volume of these stocks is deviating from the norm in today's session.
Unusual volume stocks are being observed in Friday's session.
On Thursday, there are stocks with unusual volume. Let's take a look.
Which stocks have an unusual volume on Thursday?
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-17 | Equels Thomas K | +24,000 | $0.208 | $4,992 |
| 2026-09-16 | Equels Thomas K | +11,000 | $0.21 | $2,310 |
| 2026-09-15 | Equels Thomas K | +22,000 | $0.221 | $4,862 |
| 2026-09-14 | Equels Thomas K | +5,900 | $0.219 | $1,292 |
| 2026-03-12 | Equels Thomas K | -25 | - | - |
| 2026-03-12 | Equels Thomas K | +25,000 | - | - |
| 2026-03-12 | CHEMEROW DAVID I. | -25 | - | - |
| 2026-03-12 | CHEMEROW DAVID I. | +25,000 | - | - |
| 2026-03-06 | Equels Thomas K | +50,000 | - | - |
| 2026-03-06 | Equels Thomas K | +25 | $25000 | $625,000 |
| 2026-03-06 | CHEMEROW DAVID I. | +50,000 | - | - |
| 2026-03-06 | CHEMEROW DAVID I. | +25 | $25000 | $625,000 |
| 2026-02-05 | CHEMEROW DAVID I. | +2,800 | $1.23 | $3,444 |